Leukemia, Myeloid

Oncology

Prevalence

5.0 / 100K

13 drugs in development·7 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
azacitadine	GH Research PLC (GHRS)
Cytarabine	Merus N.V. (MRUS)
Cytarabine + Daunorubicin + Gilteritinib	Merus N.V. (MRUS)

Phase 2(3)

Phase 1(4)

Drug	Company
ascentage pharma hqp1351 bioavailable inhibitor	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Bleximenib	Merus N.V. (MRUS)
blinatumomab	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
jnj-90189892	GH Research PLC (GHRS)

Phase 1/Phase 2(1)

Drug	Company
mb-dnpm1-tcr.1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)

Phase 2/Phase 3(2)

Drug	Company
annamycin	Moleculin Biotech, Inc. (MBRX)
liposomal annamycin	Moleculin Biotech, Inc. (MBRX)

BioSniper tracks 13 drugs in development for Leukemia, Myeloid across 7 companies.

There are 2 clinical trials targeting Leukemia, Myeloid tracked by BioSniper.

The estimated prevalence of Leukemia, Myeloid is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.